June 3, 2020
The Ministry of Health, Labor and Welfare (MHLW) on June 1 ordered label revisions for Nippon Shinyaku’s pulmonary arterial hypertension (PAH) treatment Uptravi (selexipag) and Sanofi’s antiplatelet Plavix (clopidogrel), by removing contradictions for their combined use. The revised labels will...read more